` BXN (Bioxyne Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BXN
vs
S
S&P/ASX 300

Over the past 12 months, BXN has significantly outperformed S&P/ASX 300, delivering a return of +67% compared to the S&P/ASX 300's +5% growth.

Stocks Performance
BXN vs S&P/ASX 300

Loading
BXN
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BXN vs S&P/ASX 300

Performance Gap Between BXN and AXKO
HIDDEN
Show

Performance By Year
BXN vs S&P/ASX 300

Loading
BXN
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bioxyne Ltd vs Peers

S&P/ASX 300
BXN
OR
ULVR
HINDUNILVR
HLN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bioxyne Ltd
Glance View

Market Cap
86.6m AUD
Industry
Consumer products

Bioxyne Ltd. engages in the research, development, market and distribution of health products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-12-14. The firm is engaged in the development of, manufacture, marketing and distribution of consumer dietary supplements based on the probiotic strain of Lactobacillus Fermentum PCC. The firm operates through two segments wholesale sales and direct sales. The firm manufactures, market, supplies and distributes its probiotic strain for over the counter dietary supplement products for the food, health, pharmaceutical and agricultural businesses. The firm is focusing on developing a range of functional food and beauty products.

BXN Intrinsic Value
HIDDEN
Show
Back to Top